Cardio- and Neurometabolic Adipobiology: Consequences and Implications for Therapy.

Autor: Frohlich J; International Clinical Research Center, St. Anne's University Hospital, 656 91 Brno, Czech Republic., Chaldakov GN; Department of Anatomy and Cell Biology and Research Institute of the Medical University, 9002 Varna, Bulgaria.; Department of Translational Stem Cell Biology, Research Institute of the Medical University, 9002 Varna, Bulgaria., Vinciguerra M; International Clinical Research Center, St. Anne's University Hospital, 656 91 Brno, Czech Republic.; Department of Translational Stem Cell Biology, Research Institute of the Medical University, 9002 Varna, Bulgaria.
Jazyk: angličtina
Zdroj: International journal of molecular sciences [Int J Mol Sci] 2021 Apr 16; Vol. 22 (8). Date of Electronic Publication: 2021 Apr 16.
DOI: 10.3390/ijms22084137
Abstrakt: Studies over the past 30 years have revealed that adipose tissue is the major endocrine and paracrine organ of the human body. Arguably, adiopobiology has taken its reasonable place in studying obesity and related cardiometabolic diseases (CMDs), including Alzheimer's disease (AD), which is viewed herein as a neurometabolic disorder. The pathogenesis and therapy of these diseases are multiplex at basic, clinical and translational levels. Our present goal is to describe new developments in cardiometabolic and neurometabolic adipobiology. Accordingly, we focus on adipose- and/or skeletal muscle-derived signaling proteins (adipsin, adiponectin, nerve growth factor, brain-derived neuroptrophic factor, neurotrophin-3, irisin, sirtuins, Klotho, neprilysin, follistatin-like protein-1, meteorin-like (metrnl), as well as growth differentiation factor 11) as examples of metabotrophic factors (MTFs) implicated in the pathogenesis and therapy of obesity and related CMDs. We argue that these pathologies are MTF-deficient diseases. In 1993 the "vascular hypothesis of AD" was published and in the present review we propose the "vasculometabolic hypothesis of AD." We discuss how MTFs could bridge CMDs and neurodegenerative diseases, such as AD. Greater insights on how to manage the MTF network would provide benefits to the quality of human life.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje